Syphilis, Gonorrhea, and the Quiet Comeback: Why STIs Are Winning Against Modern Medicine

For much of the late twentieth century, public health officials in the United States operated under a cautious but reasonable optimism: sexually transmitted infections, while never fully eradicated, were at least trending in the right direction. Syphilis rates had fallen to historic lows by the early 2000s. Gonorrhea, though persistent, appeared manageable. Then the numbers reversed.

By the mid-2020s, the Centers for Disease Control and Prevention was reporting decades-high rates of syphilis, gonorrhea, and chlamydia across the country. Congenital syphilis—a condition in which the infection passes from a pregnant person to their newborn—had increased by more than tenfold over a ten-year period, resulting in infant deaths that public health specialists described as entirely preventable. The question confronting clinicians, policymakers, and researchers is not merely statistical. It is systemic: how did a nation with functional antibiotics, established screening protocols, and a robust public health apparatus arrive at this point?

The Epidemiological Paradox

The resurgence of sexually transmitted infections in the United States presents what epidemiologists sometimes call a paradox of abundance. The tools to diagnose and treat syphilis, gonorrhea, and chlamydia have existed for decades. Penicillin remains effective against syphilis. Chlamydia responds reliably to azithromycin or doxycycline. Yet availability of treatment does not automatically translate into access to treatment, and access to treatment does not guarantee that individuals receive it before transmitting infection to others.

The gap between what medicine can do and what the healthcare system actually delivers is where the resurgence lives. Screening rates remain inadequate in many populations at elevated risk. Many Americans have no regular primary care provider. Others face financial barriers that render a visit to a sexual health clinic economically prohibitive, particularly in states that have declined to expand Medicaid under the Affordable Care Act. In rural communities, the nearest public health clinic may be more than an hour's drive away—a distance that, for someone without reliable transportation or paid sick leave, effectively closes the door on routine STI testing.

Antimicrobial Resistance: A Biological Complication

While systemic failures account for much of the resurgence, biology has introduced its own complications. Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, has demonstrated a remarkable capacity to develop resistance to successive generations of antibiotics. The organism has acquired resistance to penicillin, tetracyclines, fluoroquinolones, and, increasingly, the cephalosporins that now represent the last widely available treatment option.

The CDC has designated drug-resistant gonorrhea an urgent public health threat. Cases of extensively drug-resistant strains—infections for which no standard treatment reliably succeeds—have been documented in the United States and among American travelers returning from abroad. The pipeline for new antibiotics targeting gonorrhea is narrow. Several candidate drugs are in clinical trials, but regulatory approval and widespread clinical availability remain years away for most.

Syphilis, by contrast, has not yet developed clinically significant resistance to penicillin, which remains the treatment of choice. The challenge with syphilis is not pharmacological but logistical: the infection is frequently asymptomatic in its early stages, meaning infected individuals may transmit the bacterium for months or years before a diagnosis is ever made.

The Education Deficit

Americans receive widely varying levels of sexual health education depending on the state, school district, and community in which they grow up. Federal funding streams have historically supported abstinence-only or abstinence-until-marriage programs that, according to multiple peer-reviewed studies, do not reduce rates of sexual activity and are associated with worse STI and pregnancy outcomes compared to comprehensive sex education.

Many young adults entering their most sexually active years lack foundational knowledge about STI transmission, the importance of routine testing, or the availability of free or low-cost screening resources. This knowledge deficit is not evenly distributed. It falls disproportionately on communities that already face structural barriers to healthcare—low-income populations, communities of color, rural residents, and individuals who are incarcerated or recently released from incarceration.

The consequences are measurable. States with the most restrictive sexual health education policies consistently rank among those with the highest STI rates. This correlation does not establish causation in isolation, but it aligns with what public health researchers have documented for decades: information is a prerequisite for prevention.

Structural Inequity and the Geography of Risk

The resurgence of sexually transmitted infections in the United States is not a uniform phenomenon. It concentrates in specific populations and geographies in ways that reflect broader patterns of social inequity. Black Americans bear a disproportionate burden of syphilis and gonorrhea diagnoses relative to their share of the population—a disparity driven not by behavior but by differential access to healthcare, higher rates of poverty, residential segregation that limits healthcare facility proximity, and a history of medical mistrust rooted in documented abuses.

Men who have sex with men remain disproportionately affected by syphilis, though the current resurgence has expanded well beyond this demographic, with heterosexual transmission now accounting for a growing share of new cases. Women of reproductive age are increasingly represented in syphilis surveillance data, which directly explains the rise in congenital cases.

Public health departments, which serve as the backbone of STI prevention and contact tracing, have faced sustained funding reductions over the past two decades. Many local health departments that once employed dedicated disease intervention specialists—professionals responsible for locating and notifying sexual contacts of infected individuals—have seen those positions eliminated or consolidated. The infrastructure that once contained outbreaks has been systematically reduced at the same time that case counts have climbed.

What Evidence-Based Policy Would Require

Reversing the current trajectory is not a matter of discovering new science. The evidence base for effective STI prevention is well established. Comprehensive sexual health education reduces transmission. Expanded access to routine screening, including at-home testing options, increases diagnosis rates. Robust contact tracing interrupts transmission chains. Adequate funding for public health departments provides the workforce to execute these interventions.

Several jurisdictions have demonstrated what focused investment can accomplish. Cities that expanded STI clinic hours, reduced cost barriers, and integrated sexual health screening into primary care settings have documented measurable reductions in transmission. The challenge is scaling these models nationally and sustaining them through the political cycles that tend to defund public health programs between crises.

Antimicrobial stewardship also warrants attention. Preserving the efficacy of existing antibiotics requires surveillance systems capable of detecting resistance early, clinical guidelines that reflect current resistance patterns, and investment in novel therapeutics before the existing arsenal is exhausted.

A Preventable Crisis

The resurgence of sexually transmitted infections in the United States is, by virtually every measure, a preventable crisis. It reflects not the limits of medical knowledge but the limits of political will and equitable resource distribution. Syphilis, gonorrhea, and chlamydia do not discriminate. The systems meant to contain them, however, have never been equally accessible to all Americans.

Addressing this resurgence demands the same evidence-based rigor applied to any infectious disease emergency: honest surveillance, targeted intervention, removal of structural barriers to care, and sustained investment in the public health infrastructure that makes prevention possible. The pathogens have not changed. The question is whether the policy response will.